+Vote!
Medical News Today (Free subscription) | yesterday
Two complementary guidelines on the diagnosis and treatment of allergic rhinitis are published in the August issue of the Allergy journal. These guidelines are the result of a close cooperation between scientists, primary care professionals, and patients' organisations. GA²LEN, Global Allergy and Asthma European Network contributed to the guidelines representing European research in the field.
+Vote!
Medical News Today (Free subscription) | 07/18/2008
Schering-Plough Corporation (NYSE: SGP) announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day.
+Vote!
Allergy and Asthma Source (Free subscription) | 07/09/2008
Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008 Mar;100(3):256-63. BACKGROUND: Sublingual immunotherapy (SLIT) is increasingly being used for the treatment of allergic rhinitis, but there are conflicting study results demonstrating clinically relevant efficacy....
+Vote!
Pharmalot (Free subscription) | 06/27/2008
Could it be? Are they getting a divorce over Vytorin? No, sorry to excite you. But the drugmakers are ending their respiratory joint venture and their eight-year effort to market a combination of their Claritin and Singulair medications, which are used to treat allergic rhinitis. Here is the statement. You may recall that the FDA issued [...]
+Vote!
Red Orbit (Free subscription) | 06/25/2008
Morria Biopharmaceuticals has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm.
+Vote!
Reuters UK (Free subscription) | 06/24/2008
NEW YORK (Reuters Health) - People with persistent allergic rhinitis -- better known as hay fever -- may experience a progressive worsening of nasal airflow depending on how long they have the disorder, according to Italian researchers.
+Vote!
Reuters (Free subscription) | 06/24/2008
NEW YORK (Reuters Health) - People with persistent allergic rhinitis -- better known as hay fever -- may experience a progressive worsening of nasal airflow depending on how long they have the disorder, according to Italian researchers.
+Vote!
HotMed.info (Free subscription) | 06/23/2008
Fluticasone is a potent synthetic corticosteroid often prescribed as treatment for asthma and allergic rhinitis. The related fluticasone propionate is marketed with the brand names Flixotide (UK) for asthma and Flixonase (UK) for allergic rhinitis by Allen & Hanburys. In the US, it is marketed for asthma as Flovent, and allergic rhinitis as Flonase, by GlaxoSmithKline. [...]
+Vote!
Thaindian News (Free subscription) | 06/16/2008
Allergic rhinitis, often called allergies or hay fever, occurs when yourimmune system overreacts to particles in the air that you breathe—you are allergic to them. Your immune system attacks the particles in your body, causing symptoms such as sneezing and a runny nose. People with allergies usually have symptoms for many years. You may have symptoms [...]
1Vote!
Medical News Today (Free subscription) | 06/12/2008
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR).
+Vote!
Red Orbit (Free subscription) | 06/11/2008
LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR).
+Vote!
PR News Wire (Free subscription) | 06/11/2008
LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a
biopharmaceutical company focused on the development of novel
anti-inflammatory drugs, today announced that it has obtained regulatory
approval from the South African Medicines Control Council (MCC) to initiate
a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis
(AR). The two-arm, randomized, multi-dose, double-blind,...
2Vote!
Medical News Today (Free subscription) | 06/11/2008
New data presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology (EAACI) in Barcelona, Spain, demonstrate AERIUS® (desloratadine) significantly reduces allergy symptoms, including nasal congestion, sneezing, rhinorrhea, nasal pruritus and ocular pruritus, in patients with intermittent allergic rhinitis (IAR) who experience symptoms lasting less than four days...
2Vote!
Medical News Today (Free subscription) | 06/08/2008
In Addition to Effects on Allergic Rhinitis (Hayfever), GRAZAX(R)Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to16 Years Old. ALK-Abelló today presented successful results from a new clinical trial,GT-12, designed to measure the impact of GRAZAX(R) on allergic rhinitis andallergic asthma.
1Vote!
sunilnair | 12/26/2007
Immunotherapy in Allergic Rhinitis - Moving away from injections Introduction Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead...
